Akero Therapeutics
Cambridge
About Akero Therapeutics
Akero Therapeutics is a biopharmaceutical company focused on developing therapies for patients with serious metabolic diseases. The company’s pipeline centers on the development of Efruxifermin (EFX) for the treatment of pre-cirrhotic MASH, formerly known as NASH. Akero Therapeutics conducts clinical trials and research programs related to its therapeutic focus.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Total funding: $951.1M
- Funding stage: M&A
- Last round: Post-IPO Equity (Mar 2024)
- Ticker: nasdaq:AKRO
- Website: akerotx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/akero-therapeutics-5188 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.